These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37036495)

  • 21. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
    Shannon HE; Rasmussen K; Bymaster FP; Hart JC; Peters SC; Swedberg MD; Jeppesen L; Sheardown MJ; Sauerberg P; Fink-Jensen A
    Schizophr Res; 2000 May; 42(3):249-59. PubMed ID: 10785583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
    Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
    Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
    Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
    J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia.
    Kidambi N; Elsayed OH; El-Mallakh RS
    Neuropsychiatr Dis Treat; 2023; 19():1145-1151. PubMed ID: 37193547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
    Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
    ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
    Jakubík J; Tucek S; El-Fakahany EE
    J Pharmacol Exp Ther; 2004 Jan; 308(1):105-10. PubMed ID: 14569060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
    Leber A; Ramachandra R; Ceban F; Kwan ATH; Rhee TG; Wu J; Cao B; Jawad MY; Teopiz KM; Ho R; Le GH; Ramachandra D; McIntyre RS
    Expert Opin Pharmacother; 2024 Mar; 25(4):467-476. PubMed ID: 38515004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of muscarinic M
    Stoll K; Hart R; Lindsley CW; Thomsen M
    Psychopharmacology (Berl); 2018 Mar; 235(3):815-827. PubMed ID: 29250738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
    Sramek JJ; Hurley DJ; Wardle TS; Satterwhite JH; Hourani J; Dies F; Cutler NR
    J Clin Pharmacol; 1995 Aug; 35(8):800-6. PubMed ID: 8522637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xanomeline and Trospium: A Potential Fixed Drug Combination (FDC) for Schizophrenia-A Brief Review of Current Data.
    Singh A
    Innov Clin Neurosci; 2022; 19(10-12):43-47. PubMed ID: 36591549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
    Dean B
    Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review.
    Vasiliu O; Budeanu B; Cătănescu MȘ
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
    De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
    Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
    Dean B; Scarr E
    Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
    Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
    Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
    Martino G; Puma C; Yu XH; Gilbert AK; Coupal M; Markoglou N; McIntosh FS; Perkins MN; Laird JMA
    Pain; 2011 Dec; 152(12):2852-2860. PubMed ID: 22018972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW; Cohen ML
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.